A Study of MK-0616 in Participants With Moderate Renal Impairment

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This purpose of this study is to compare the pharmacokinetics (PK) of a single dose of MK-0616 in participants with moderate renal impairment (RI) to those of healthy matched control participants. This study is being conducted to assess the impact of moderate renal insufficiency on the PK of MK-0616.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02128490` - Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment	Phase 2
	Completed	`NCT02742103` - A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction	Phase 2

NCT number	NCT05070390
Study type	Interventional
Source	Merck Sharp & Dohme LLC
Contact
Status	Completed
Phase	Phase 1
Start date	November 16, 2021
Completion date	May 3, 2023

A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms